Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Sage Therapeutics but lowers the price target from $17 to $14.

October 30, 2024 | 6:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Scotiabank has maintained its Sector Outperform rating for Sage Therapeutics but has reduced the price target from $17 to $14, indicating a more cautious outlook.
The reduction in the price target from $17 to $14 suggests a more cautious outlook on Sage Therapeutics' stock performance, which could lead to a short-term negative impact on the stock price. However, the maintained Sector Outperform rating indicates continued confidence in the company's long-term potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100